Botensilimab/balstilimab data in mss crc selected for the american society of clinical oncology 2024 annual meeting

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the phase 1b trial of botensilimab in combination with balstilimab (“bot/bal”) in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r mss crc nlm) will be presented at the upcoming american society of clinical oncology (asco) meeting, to be hel.
AGEN Ratings Summary
AGEN Quant Ranking